Litchev Boyan Vesselinov
Known title: Chief Medical OfficerCIK: 0001902726
Litchev Boyan Vesselinov's purchase track record
How the stock did after each of Litchev Boyan Vesselinov's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since January 31, 2022
Stock higher 6 months later
25%
3 months: 0%
Median 6-month return
-20.5%
3 months: -20.6%
Beat the S&P 500
25%
median -17.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/1/2022 | INDP | $935 | -2.2% | -2.8% | +3.5% |
| 11/22/2022 | INDP | $915 | -3.3% | +14.3% | +3.5% |
| 3/2/2022 | INDP | $205 | -39.7% | -38.2% | -9.8% |
| 1/31/2022 | INDP | $465 | -37.9% | -45.5% | -8.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| INDP | ▲ Buy | Open Market | 500 | $935 | 12/1/2022 | View on chart |
| INDP | ▲ Buy | Open Market | 500 | $915 | 11/22/2022 | View on chart |
| INDP | ▲ Buy | Open Market | 50 | $205 | 3/2/2022 | View on chart |
| INDP | ▲ Buy | Open Market | 100 | $465 | 1/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Indaptus named among top small-cap healthcare performers
Indaptus Therapeutics was highlighted in a recent report as one of five smaller health care stocks that outperformed Moderna in September. The stock is currently trading near the upper end of its 52-week range, reflecting this recent strength. This inclusion in a performance-based list draws attention to the company's recent market activity relative to larger peers.
Indaptus named among top small-cap healthcare performers. Indaptus Therapeutics was highlighted in a recent report as one of five smaller health care stocks that outperformed Moderna in September. The stock is currently trading near the upper end of its 52-week range, reflecting this recent strength. This inclusion in a performance-based list draws attention to the company's recent market activity relative to larger peers.